RxDoctor Payments Data

Douglas Yozwiak, PA

Physician Assistant · Lexington, KYNPI 1386919694

Payments from drug & device makers

$387in general payments, 2019–2025

Across 19 payments — averaging $20.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Antares Pharma, Inc.$86
  • AbbVie$84
  • Endo Pharmaceuticals Inc.$81
  • Tolmar, Inc.$63
  • Axonics, Inc.$24
  • Ascend Therapeutics US, LLC$21
  • plus $28 from 2 others

What the payments were for

  • Food & beverage$387100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Antares Pharma, Inc.5$86
AbbVie1$84
Endo Pharmaceuticals Inc.5$81
Tolmar, Inc.4$63
Axonics, Inc.1$24
Ascend Therapeutics US, LLC1$21
Urovant Sciences Inc1$15
Myovant Sciences Inc.1$13

How this compares

$387 in reported general payments places this provider in the 50th percentile of 1,448 physician assistant providers in Kentucky.

See all physician assistant providers in Kentucky

Medicare billing

Part B allowed, 2024
$99,801
Medicare patients
378
Services billed
1,856

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide35$48,616
EliquisApixaban61$36,316
JardianceEmpagliflozin26$17,723
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$14,660
XareltoRivaroxaban15$13,512
Albuterol Sulfate HfaAlbuterol Sulfate75$1,761
PaxlovidNirmatrelvir/Ritonavir21$1,429
SynthroidLevothyroxine Sodium17$1,228
Gabapentin92$1,084
Lisinopril116$781
Levothyroxine Sodium113$771
Metoprolol Succinate79$747
Losartan Potassium116$737
Bumetanide24$679
Zafirlukast13$677

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$84$1,22817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,448 physician assistant providers in Kentucky.

Other physician assistant in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →